Zentalis Pharmaceuticals, Inc.
ZNTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001725160
In the last 90 days, Zentalis Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 114 institutions reported holding it in 13F filings for Q2 2026, worth $228.9M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $15.2M in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +14 vs. previous quarter
- 114
- 13F valueReported value at the end of Q2 2026
- $228.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ZNTL, Q2 2026
No superinvestor reported holding ZNTL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Zentalis Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 (view filing)6:11 PM ET | Aug 14 | 5 daysLate | Walters Group and 2 others10% Owner | PPurchase | +4.33M | $3.50 | +$15.2M | +32.1%17.8M after | |
| Feb 10, 2026 (view filing) | Feb 6-10 | 4 days | Vultaggio VincentPAO and PFO | SSale | −40.2K | $2.42 | −$97.5K | −21.5%146.5K after | 3 lots10b5-1 |
| Feb 10, 2026 (view filing) | Feb 6-9 | 4 days | Bruns IngmarChief Medical Officer | SSale | −3.30K | $2.43 | −$8.00K | −9.0%33.3K after | 2 lots |
| Feb 10, 2026 (view filing) | Feb 6-9 | 4 days | Eastland Julia MarieCEO & President | SSale | −8.76K | $2.43 | −$21.2K | −10.0%79.1K after | 2 lots |
| Feb 4, 2026 (view filing) | Feb 2-3 | 2 days | Vultaggio VincentPAO and PFO | SSale | −3.10K | $2.54 | −$7.88K | −1.6%186.7K after | 2 lots10b5-1 |
| Jan 8, 2026 (view filing)4:57 PM ET | Dec 31, 2025 | 8 daysLate | Walters Group and 2 others10% Owner | PPurchase | +6.46M | $1.20 | +$7.75M | +91.6%13.5M after | |
| Dec 15, 2025 (view filing)5:24 PM ET | Dec 15 | Same day | Matrix Capital Management Company, LP and 1 other10% Owner | SSaleCommon Stock, par value $0.001 per share | −7.50M | $1.33 | −$9.97M | −53.7%6.46M after | |
| Apr 30, 2025 (view filing) | Apr 30 | Same day | Myers Scott DunsethDirector | PPurchase | +21.0K | $1.40 | +$29.4K | +8.1%281.2K after | |
| Feb 12, 2025 (view filing) | Feb 6 | 6 daysLate | Bruns IngmarChief Medical Officer | PPurchase | +20.0K | $2.28 | +$45.6K | +120.3%36.6K after | |
| Feb 5, 2025 (view filing) | Feb 3 | 2 days | Vultaggio VincentPAO and Interim PFO | SSale | −2.62K | $1.71 | −$4.47K | −1.4%189.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Zentalis Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| 5AM Venture Management, LLC | 3,947,913 | $19.1M | 6.65% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,753,525 | $18.2M | 0.00% | +2,483,688+195.6% | Added |
| Squadron Capital Management LLC | 3,700,000 | $17.9M | 6.14% | +69,000+1.9% | Added |
| Two Sigma Investments, LP | 3,024,936 | $14.7M | 0.01% | +68,410+2.3% | Added |
| Vanguard Capital Management LLC | 2,835,669 | $13.8M | 0.00% | +524,962+22.7% | Added |
| Acadian Asset Management LLC | 2,681,900 | $13.0M | 0.02% | −166,352−5.8% | Reduced |
| Citadel Advisors LLC | 2,298,403 | $11.1M | 0.01% | +566,320+32.7% | Added |
| Renaissance Technologies LLC | 1,609,078 | $7.80M | 0.01% | −329,067−17.0% | Reduced |
| Opaleye Management Inc. | 1,412,656 | $6.85M | 0.62% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 1,390,576 | $6.74M | 0.13% | +1,390,576 | New |